Role of exogenous arginine vasopressin in the management of catecholamine-refractory septic shock

Critical Care Nurse

Volumn 26, Issue 6, 2006, Pages 17-23

  Lee, Christopher S ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CATECHOLAMINE; VASOCONSTRICTOR AGENT;

BLOOD PRESSURE; CASE REPORT; CLINICAL TRIAL; DRUG EFFECT; DRUG MONITORING; HEART OUTPUT; HEART RATE; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; NURSING; PATHOPHYSIOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ARGININE VASOPRESSIN; BLOOD PRESSURE; CARDIAC OUTPUT; CATECHOLAMINES; CLINICAL TRIALS; CRITICAL CARE; DRUG MONITORING; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RESEARCH DESIGN; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 39049177721     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-1256.
2. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2002;345:1368-1377.
3. Sessler CN, Perry JC, Varney KL. Management of severe sepsis and septic shock. Curr Opin Crit Care. 2004;10:354-363.
4. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med. 2004;30:597-604.
5. Bridges EJ, Dukes MS. Cardiovascular aspects of septic shock: pathophysiology, monitoring, and treatment. Crit Care Nurse. April 2005;25:14-16, 18-20, 22-24 passim.
6. Dünser MW, Fries DR, Schobersberger W, et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg. 2004;99:201-206.
7. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [published corrections appear in Crit Care Med. 2004;32:1448 and 2004;32:2169]. Crit Care Med. 2004;32:858-873.
8. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576-582.
9. Malay MB, Ashton RC, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47:699-703.
10. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med. 2003;31:1752-1758.
11. Sessler CN, Shepherd W. New concepts in sepsis. Curr Opin Crit Care. 2002;8:465-472.
12. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized controlled study. Circulation. 2003;107:2313-2319.
13. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA III. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001;29:487-493.
14. van Haren FMP, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest. 2003;124: 2256-2260.
15. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest. 2001;120:989-1002.
16. Lingappa VR. Disorders of the hypothalamus and pituitary gland. In: McPhee SJ, Lingappa VR, Ganong WF, eds. Pathophysiology of Disease: An Introduction to Clinical Medicine. New York, NY: Lange Medical Books; 2003:539-540.
17. Rhoades R, Pflanzer R. Human Physiology. 4th ed. Pacific Grove, Calif: Thompson Brooks/Cole; 2003:415, 768-773.
18. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med. 2003;31:2646-2650.
19. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122-1125.
20. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279-1282.
21. Obritsch MD, Jung R, Fish DN, MacLaren R. Effects of vasopressin infusion in patients with septic shock. Ann Pharmacother. 2004;38:1117-1122.
22. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005;33:1897-1902.
23. Russell JA. Vasopressin in septic shock: clinical equipoise mandates a time for restraint. Crit Care Med. 2003;31:2707-2709.
24. Dünser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003;31:1394-1398.
25. Russell JA. A randomized controlled trial of vasopressin versus norepinephrine in septic shock. Available at: http://www.controlled-trials.com/ISRCTN94845869. Accessed September 7, 2006.
26. Holmes CL, Walley KR. Vasopressin in the ICU. Curr Opin Crit Care. 2004;10:442-448.
27. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, part 7.20: management of cardiac arrest. Circulation. 2005;112(suppl):IV56-IV58.